½ÃÀ庸°í¼­
»óǰÄÚµå
1720690

¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå º¸°í¼­(2025³â)

Acute Care Syndromic Testing Global Market Report 2025

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Business Research Company | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä ¹ßÀü µ¿Çâ¿¡´Â ÇöÀå °Ë»ç·ÎÀÇ ½ÃÇÁÆ®, Ŭ¶ó¿ìµå ±â¹ÝÀÇ Ç÷§ÆûÀÇ ÅëÇÕ, ¸ÖƼÇ÷º½º ÆÐ³ÎÀÇ Ã¤¿ë, AI žÀç ÅøÀÇ °³¹ß, ½Åµå·Î¹Í °Ë»ç¿¡ À־ÀÇ ÀÚµ¿È­ÀÇ ÁøÀü µîÀÌ ÀÖ½À´Ï´Ù.

°¨¿°ÁõÀÇ À¯Çà Áõ°¡´Â ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°è ¿©Çà, Ç×±ÕÁ¦ ³»¼º, ±âÈÄ º¯È­ µîÀÇ ¿äÀÎÀÌ ÀÌ·¯ÇÑ Áúº´ÀÇ ¹ß»ý·ü »ó½Â¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Áø´Ü¡¤Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù ¿µ±¹ °Ç°­º¸°Ç±¹Àº 2024³â 4ÁÖ ÀÎÇ÷翣ÀÚ ¾ç¼º·üÀÌ ÀüÁÖÀÇ 14.0%¿¡¼­ 16.6%·Î »ó½ÂÇß´Ù°í º¸°íÇß½À´Ï´Ù. Áø´Ü·üµµ »ó½ÂÇØ 10¸¸¸í´ç 9.8¸í(ÀüÁÖ´Â 7.5¸í)¿¡ À̸£·¶°í, ÀÎÇ÷翣ÀÚ¿¡ ÀÇÇÑ ÀÔ¿ø ȯÀÚ¼ö´Â 10¸¸¸í´ç 5.12¸í¿¡¼­ 7.63¸íÀ¸·Î Áõ°¡Çß½À´Ï´Ù.

±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀåÀÇ ¼±µµ ±â¾÷µéÀº Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í, ½Å¼ÓÇÑ º´¿øÃ¼ °ËÃâÀ» °¡´ÉÇÏ°Ô Çϸç, ½ÇÇè½Ç ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí, ó¸® ½Ã°£À» ´ÜÃàÇϱâ À§ÇØ ¸ÖƼÇ÷º½º ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) ±â¼úÀÇ ¹ßÀüÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸ÖƼÇ÷º½º ½Ç½Ã°£ PCRÀº ÇÑ ¹øÀÇ ¹ÝÀÀÀ¸·Î ¿©·¯ º´¿øÃ¼ ¶Ç´Â À¯ÀüÀÚ Ç¥ÀûÀ» µ¿½Ã¿¡ °ËÃâÇϰí Á¤·®È­Çϴ ÷´Ü ºÐÀÚ Áø´Ü ¹æ¹ýÀ¸·Î, Áúº´ Áø´ÜÀÇ È¿À²¼º°ú Á¤È®¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. 2023³â 4¿ù, QIAGEN N.V.´Â ÀϺ»¿¡¼­ QIAstat-Dx ½Åµå·Î¹Í °Ë»ç ¼Ö·ç¼ÇÀ» Ãâ½ÃÇß½À´Ï´Ù. 2022³â ¸»±îÁö ¼¼°è 3,500´ë ÀÌ»óÀÇ QIAstat-Dx ½Ã½ºÅÛÀÌ µµÀԵǾî È£Èí±â, ¼ÒÈ­±â, ¼ö¸·¿° °ü·Ã ÁúȯÀÇ Áø´Ü¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

  • ¼¼°èÀÇ ±Þ¼º±âÀÇ·á ½Åµå·Î¹Í °Ë»ç PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ)
  • ÃÖÁ¾ ÀÌ¿ë »ê¾÷ÀÇ ºÐ¼®
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : ¼ºÀå·ü ºÐ¼®
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå ½ÇÀû : ±Ô¸ð¿Í ¼ºÀå(2019-2024³â)
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå ¿¹Ãø : ±Ô¸ð¿Í ¼ºÀå(2024-2029³â, 2034³â)
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç Àüü ½ÃÀå(TAM)

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : Áúȯ À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • È£Èí±â Áúȯ
  • À§Àå Áúȯ
  • ºñ´¢»ý½Ä±â Áúȯ
  • ¿­´ë¼º Áúȯ
  • ±âŸ Áúȯ À¯Çü
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : »ùÇà À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • Ç÷¾×
  • ¼Òº¯
  • ü¾×
  • ´ëº¯
  • ¸éºÀ
  • ±âŸ »ùÇà À¯Çü
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : Ÿ°Ùº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¹ÚÅ׸®¾Æ
  • ¹ÙÀÌ·¯½º
  • °õÆÎÀÌ
  • ±â»ýÃæ
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • º´¿ø
  • ÀÓ»ó ¹× Áø´Ü½ÇÇè½Ç
  • ¿¬±¸ ¹× Çмú ±â°ü
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : È£Èí±â Áúȯ À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ÀÎÇ÷翣ÀÚ
  • È£Èí±â ¼¼Æ÷À¶ÇÕ ¹ÙÀÌ·¯½º(RSV)
  • COVID-19
  • °áÇÙ
  • ±âŸ È£Èí±â Áúȯ
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : À§Àå Áúȯ À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • Ŭ·Î½ºÆ®¸®µã µðÇÇ½Ç °¨¿°Áõ
  • ³ë·Î¹ÙÀÌ·¯½º
  • ·ÎŸ¹ÙÀÌ·¯½º
  • »ì¸ð³Ú¶ó±Õ
  • ±âŸ À§Àå Áúȯ
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : ºñ´¢»ý½Ä±â Áúȯ À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¿ä·Î °¨¿°(UTI)
  • ¼ºº´(STI)
  • Áú °¨¿°
  • ±âŸ ºñ´¢»ý½Ä±â Áúȯ
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : ¿­´ë¼º Áúȯ À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¸»¶ó¸®¾Æ
  • µ­±â¿­
  • Ä¡Äﱸ´Ï¾Æ
  • ÁöÄ« ¹ÙÀÌ·¯½º
  • ±âŸ ¿­´ë¼º Áúȯ
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå, ±âŸ Áúȯ À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ³ú¼ö¸·¿°
  • ÆÐÇ÷Áõ
  • ±âŸ ½ÅÁ¾ °¨¿°º´

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : Áö¿ªº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¼¼°èÀÇ ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : ±¹°¡º°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : °æÀï ±¸µµ
  • ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå : ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Siemens Healthineers AG °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • F. Hoffmann-La Roche Ltd °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • Thermo Fisher Scientific Inc. °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • Danaher Corporation °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • Becton, Dickinson and Company °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

  • Seegene Inc.
  • bioMerieux SA
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Werfen
  • DiaSorin SpA
  • Quidel Corporation
  • Luminex Corporation
  • Biocartis NV
  • Microbiologics Inc.
  • QuantuMDx Group Ltd.
  • Curetis GmbH by OpGen Inc.
  • Genetic Signatures Ltd.
  • Applied BioCode Inc.

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

  • ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
  • ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
  • ±Þ¼º±â ÀÇ·á ½Åµå·Î¹Í °Ë»ç ½ÃÀå(2029³â) : ¼ºÀå Àü·«
    • ½ÃÀå µ¿Çâ¿¡ ±âÃÊÇÑ Àü·«
    • °æÀï Àü·«

Á¦36Àå ºÎ·Ï

KTH

Acute care syndromic testing is a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. Primarily used in emergency and critical care settings, it enables quicker diagnosis of infectious diseases, leading to faster treatment decisions, improved patient outcomes, and reduced hospital stays.

The main disease types in the acute care syndromic testing market include respiratory diseases, gastrointestinal diseases, genitourinary diseases, tropical diseases, and others. Respiratory diseases affect the lungs, airways, and respiratory tract, causing symptoms such as coughing, shortness of breath, and fever. Various sample types used for testing include blood, urine, biofluids, stool, swabs, and more. The tests target bacteria, viruses, fungi, and parasites and are utilized in hospitals, clinical and diagnostic laboratories, research and academic institutions, and other healthcare settings.

The acute care syndromic testing market research report is one of a series of new reports from The Business Research Company that provides acute care syndromic testing market statistics, including the acute care syndromic testing industry's global market size, regional shares, competitors with a acute care syndromic testing market share, detailed acute care syndromic testing market segments, market trends and opportunities, and any further data you may need to thrive in the acute care syndromic testing industry. This acute care syndromic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute care syndromic testing market size has grown rapidly in recent years. It will grow from $4.08 billion in 2024 to $4.62 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to increasing awareness of antimicrobial resistance, rising government funding for infectious disease research, greater investment in healthcare infrastructure, a growing focus on syndromic testing, the expansion of telemedicine, and the rising prevalence of infectious diseases.

The acute care syndromic testing market size is expected to see rapid growth in the next few years. It will grow to $7.50 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth during the forecast period can be attributed to the rising prevalence of infectious diseases, increasing demand for faster diagnostic solutions, the expansion of healthcare services, the growing use of multiplex syndromic panels, and a rising geriatric population. Key trends expected during this period include a shift toward point-of-care testing, the integration of cloud-based platforms, the adoption of multiplex panels, the development of AI-powered tools, and increased automation in syndromic testing.

The increasing prevalence of infectious diseases is expected to drive the growth of the acute care syndromic testing market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can spread through human contact, animals, or the environment. Factors such as population growth, urbanization, global travel, antimicrobial resistance, and climate change are contributing to the rising incidence of these diseases, increasing the demand for effective diagnostic and treatment solutions. Acute care syndromic testing plays a crucial role in identifying pathogens and co-infections through multiplex molecular diagnostics, allowing for targeted treatment decisions. For example, in February 2024, the UK Health Security Agency reported that in week 4 of 2024, the influenza positivity rate rose to 16.6%, up from 14.0% the previous week. Influenza-like illness (ILI) consultations also increased, reaching 9.8 per 100,000 people compared to 7.5 per 100,000 in the prior week, while influenza hospitalizations climbed from 5.12 to 7.63 per 100,000. Consequently, the growing incidence of infectious diseases is fueling the expansion of the acute care syndromic testing market.

Leading companies in the acute care syndromic testing market are leveraging advancements in multiplex real-time polymerase chain reaction (PCR) technology to enhance diagnostic accuracy, enable rapid pathogen detection, streamline laboratory workflows, and reduce turnaround time. Multiplex real-time PCR is an advanced molecular diagnostic method that simultaneously detects and quantifies multiple pathogens or genetic targets in a single reaction, improving efficiency and accuracy in disease diagnosis. In April 2023, QIAGEN N.V., a Netherlands-based biotechnology company, launched the QIAstat-Dx syndromic testing solution in Japan. This system features a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. Using multiplex real-time PCR technology, it provides rapid results with minimal labor compared to traditional PCR assays. By the end of 2022, over 3,500 QIAstat-Dx systems had been installed worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related conditions. Available in more than 100 countries, this system is improving global access to syndromic testing.

In May 2023, Applied BioCode, a US-based biotechnology company, partnered with Medline Industries to expand the distribution of the BioCode MDx-3000 System. This collaboration aims to enhance access to diagnostic testing for hospitals and reference laboratories across the U.S. Medline Industries LP, a US-based healthcare company specializing in medical supplies and healthcare services, will support the distribution of Applied BioCode's multiplex diagnostic solutions, further advancing syndromic testing capabilities.

Major players in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., and Applied BioCode Inc.

North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in acute care syndromic testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute care syndromic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute care syndromic testing market consists of revenues earned by entities by providing services such as comprehensive pathogen detection, rapid turnaround time, and support for antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute care syndromic testing market also includes sales of blood collection tubes, or urine containers, PCR and RT-PCR machines, and reader devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Care Syndromic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute care syndromic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute care syndromic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute care syndromic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disease Type: Respiratory Diseases; Gastrointestinal Diseases; Genitourinary Diseases; Tropical Diseases; Other Disease Types
  • 2) By Sample Type: Blood; Urine; Biofluids; Stool; Swabs; Other Sample Types
  • 3) By Target: Bacteria; Viruses; Fungi; Parasites
  • 4) By End User: Hospitals; Clinical And Diagnostic Laboratories; Research And Academic Institutions; Other End Users
  • Subsegments:
  • 1) By Respiratory Diseases: Influenza; Respiratory Syncytial Virus (RSV); COVID-19; Tuberculosis; Other Respiratory Diseases
  • 2) By Gastrointestinal Diseases: Clostridium Difficile Infection; Norovirus; Rotavirus; Salmonella; Other Gastrointestinal Diseases
  • 3) By Genitourinary Diseases: Urinary Tract Infections (UTIs); Sexually Transmitted Infections (STIs); Vaginal Infections; Other Genitourinary Diseases
  • 4) By Tropical Diseases: Malaria; Dengue; Chikungunya; Zika Virus; Other Tropical Diseases
  • 5) By Other Disease Types: Meningitis; Sepsis; Other Emerging Infectious Diseases
  • Companies Mentioned: Siemens Healthineers AG; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Danaher Corporation; Becton, Dickinson and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Care Syndromic Testing Market Characteristics

3. Acute Care Syndromic Testing Market Trends And Strategies

4. Acute Care Syndromic Testing Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute Care Syndromic Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Acute Care Syndromic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Acute Care Syndromic Testing Market Growth Rate Analysis
  • 5.4. Global Acute Care Syndromic Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Acute Care Syndromic Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Acute Care Syndromic Testing Total Addressable Market (TAM)

6. Acute Care Syndromic Testing Market Segmentation

  • 6.1. Global Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Respiratory Diseases
  • Gastrointestinal Diseases
  • Genitourinary Diseases
  • Tropical Diseases
  • Other Disease Types
  • 6.2. Global Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Blood
  • Urine
  • Biofluids
  • Stool
  • Swabs
  • Other Sample Type
  • 6.3. Global Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bacteria
  • Viruses
  • Fungi
  • Parasites
  • 6.4. Global Acute Care Syndromic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinical And Diagnostic Laboratories
  • Research And Academic Institutions
  • Other End Users
  • 6.5. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Respiratory Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Influenza
  • Respiratory Syncytial Virus (RSV)
  • COVID-19
  • Tuberculosis
  • Other Respiratory Diseases
  • 6.6. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Gastrointestinal Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clostridium Difficile Infection
  • Norovirus
  • Rotavirus
  • Salmonella
  • Other Gastrointestinal Diseases
  • 6.7. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Genitourinary Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Urinary Tract Infections (UTIs)
  • Sexually Transmitted Infections (STIs)
  • Vaginal Infections
  • Other Genitourinary Diseases
  • 6.8. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Tropical Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Malaria
  • Dengue
  • Chikungunya
  • Zika Virus
  • Other Tropical Diseases
  • 6.9. Global Acute Care Syndromic Testing Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Meningitis
  • Sepsis
  • Other Emerging Infectious Diseases

7. Acute Care Syndromic Testing Market Regional And Country Analysis

  • 7.1. Global Acute Care Syndromic Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Acute Care Syndromic Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Care Syndromic Testing Market

  • 8.1. Asia-Pacific Acute Care Syndromic Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Care Syndromic Testing Market

  • 9.1. China Acute Care Syndromic Testing Market Overview
  • 9.2. China Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Care Syndromic Testing Market

  • 10.1. India Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Care Syndromic Testing Market

  • 11.1. Japan Acute Care Syndromic Testing Market Overview
  • 11.2. Japan Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Care Syndromic Testing Market

  • 12.1. Australia Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Care Syndromic Testing Market

  • 13.1. Indonesia Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Care Syndromic Testing Market

  • 14.1. South Korea Acute Care Syndromic Testing Market Overview
  • 14.2. South Korea Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Care Syndromic Testing Market

  • 15.1. Western Europe Acute Care Syndromic Testing Market Overview
  • 15.2. Western Europe Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Care Syndromic Testing Market

  • 16.1. UK Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Care Syndromic Testing Market

  • 17.1. Germany Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Care Syndromic Testing Market

  • 18.1. France Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Care Syndromic Testing Market

  • 19.1. Italy Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Care Syndromic Testing Market

  • 20.1. Spain Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Care Syndromic Testing Market

  • 21.1. Eastern Europe Acute Care Syndromic Testing Market Overview
  • 21.2. Eastern Europe Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Care Syndromic Testing Market

  • 22.1. Russia Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Care Syndromic Testing Market

  • 23.1. North America Acute Care Syndromic Testing Market Overview
  • 23.2. North America Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Care Syndromic Testing Market

  • 24.1. USA Acute Care Syndromic Testing Market Overview
  • 24.2. USA Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Care Syndromic Testing Market

  • 25.1. Canada Acute Care Syndromic Testing Market Overview
  • 25.2. Canada Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Care Syndromic Testing Market

  • 26.1. South America Acute Care Syndromic Testing Market Overview
  • 26.2. South America Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Care Syndromic Testing Market

  • 27.1. Brazil Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Care Syndromic Testing Market

  • 28.1. Middle East Acute Care Syndromic Testing Market Overview
  • 28.2. Middle East Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Care Syndromic Testing Market

  • 29.1. Africa Acute Care Syndromic Testing Market Overview
  • 29.2. Africa Acute Care Syndromic Testing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Acute Care Syndromic Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Acute Care Syndromic Testing Market, Segmentation By Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Care Syndromic Testing Market Competitive Landscape And Company Profiles

  • 30.1. Acute Care Syndromic Testing Market Competitive Landscape
  • 30.2. Acute Care Syndromic Testing Market Company Profiles
    • 30.2.1. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Becton, Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis

31. Acute Care Syndromic Testing Market Other Major And Innovative Companies

  • 31.1. Seegene Inc.
  • 31.2. bioMerieux SA
  • 31.3. Sysmex Corporation
  • 31.4. Bio-Rad Laboratories Inc.
  • 31.5. QIAGEN N.V.
  • 31.6. Werfen
  • 31.7. DiaSorin S.p.A.
  • 31.8. Quidel Corporation
  • 31.9. Luminex Corporation
  • 31.10. Biocartis NV
  • 31.11. Microbiologics Inc.
  • 31.12. QuantuMDx Group Ltd.
  • 31.13. Curetis GmbH by OpGen Inc.
  • 31.14. Genetic Signatures Ltd.
  • 31.15. Applied BioCode Inc.

32. Global Acute Care Syndromic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Care Syndromic Testing Market

34. Recent Developments In The Acute Care Syndromic Testing Market

35. Acute Care Syndromic Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Acute Care Syndromic Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Acute Care Syndromic Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Acute Care Syndromic Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦